Wednesday, May 23, 2012

Marvell Earnings Announcement

Marvell released earnings Thursday, they reported non-GAAP EPS of 23 cents per share on revenues of $796.4 million. Street analysts were expecting EPS of 20 cents per share on revenues of $768.3 million. Marvell has also initiated a quarterly dividend of 6 cents per share, and they also are expanding their share buyback program by $500 million. Mobile and wireless end market revenue grew 14% from the year ago quarter but fell 1% from last quarter, this segment made up 29% of their total revenues. They saw an increase in their storage end market revenues of 20% from their last quarter release, resulting in a recovery from the flooding in Thailand. Gross and Operating margins dropped 4.3% and 6.7%, respectively. They still carry no long term debt and have a cash and cash equivalent balance of about $2.2 billion.
Marvell released guidance for next quarter with revenues in a range of $840-890 million, representing a sequential 6-12% increase. They also expect their mobile and wireless segment to grow between 5-10% during the next quarter, due in large part to an increase in TD smartphone revenue. Non-GAAP EPS estimates for next quarter are 28 cents per share. With the Chinese mobile market continuing to grow and China Mobile continuing their investments in the TD-SCDMA and TD-LTE networks, Marvell stands to benefit from this with a strong product line in both networks. Currently higher material costs and European exposure continue to hinder the stock lower despite a good earnings release and positive outlook.
- Ryan Ranado

Tuesday, May 22, 2012

DVA Acquires HealthCare Partners 05/21/12 - (Ryan Kennedy)

On May 21st, DaVita announced the acquisition of HealthCare Partners for $3.66 billion in cash and $758 million in stock, for a total of $4.42 billion. The acquisition of HealthCare Partners represents the entrance into a new market for DaVita, a dialysis service company. HealthCare Partners is the largest medical group and physician network in the United States, and focuses on lower medical costs and positive patients outcomes. The firm provides medical services to approximately 667,000 patients through a network of 700 physicians. HealthCare Partners operates under a capitated model, in which insurers pay a fixed amount, which encourages low-cost positive outcomes, as opposed to maximizing the volume of services and prescriptions. DaVita CEO, Kent Thiry, commented that the capitated model is "where the puck is headed for American health care." In this sense, the deal can be viewed as a way to ease the transition into a capitated dialysis market. The $4.42 billion deal values HealthCare Partners at 8.4x EBITDA, and will be funded by cash on hand and the issuance of high yield debt.

Alexion Pharmaceutical (ALXN) joins the S&P 500

Shares of Alexion Pharmaceuticals (ALXN) will replace those of Motorola Mobility Holdings (MMI) within the S&P 500 index on Friday, April 25th . MMI's departure from the index is a result of its recent takeover by Goolge. Shares of ALXN jumped 4.3%, closing at $92.54 on abnormally high trading volume.Throughout the day 5.6 million shares were traded compared to the daily average of 1.2 million shares. The stock price ranged from $91.80-$94.36, after previously closing at $91.80 the day before.

LIFE F1Q12 Earnings 4/27/12 - (Jorge Perez)

Life Technologies reported earnings on Tuesday after market hours and beat analysts’ expectations with earnings per share coming in at $0.72, up from $0.50 last Q1. Revenues increased 5% year over year to $939 million. Operating margin came in at 30.2% in the first quarter, approximately 2% higher than the same period of the prior year. This was primarily due to the company’s continued focus on operational efficiencies. They recently realigned their segments into three categories, providing historical data going back to 2010, to better reflect their business model: Research Consumables, Genetic Analysis, and Applied Sciences. Revenues increased 4%, 7%, and 4%, respectively within these segments. Genetic Analysis sales were driven by robust growth of Ion Torrent and CE products, partially offset by lower sales of SOLiD products. The change in reported earnings has no effect on results of operations, financial condition, or cash flows. Regional revenue growth rates year over year were as follows: the Americas were flat, Europe grew 2%, Asia Pacific grew 8%, and Japan grew 7%. On a negative note, their ending cash and short-term investments was down to $267 million, from $887 million in 2011, due to one-time cash payments.

The company repurchased $185 million worth in shares in the first quarter with plans to purchase another $200 million in the upcoming quarters. Their return on investment capital was 9%, while they plan to reach their goal of 10% ROIC by the end of 2012. Total debt was about $2.4 billion. In the first quarter LIFE made 2 tuck-in acquisitions with no expected material impact on earnings: Matix Microsciences and LSI. Both acquisitions will better their position in the animal health and food safety businesses. They also experienced about a 6% increase in online sales and activated more distribution centers across the world. During the quarter they continued to deliver on their innovation pipeline, launching Ion AmpliSeq Custom Panels and TaqMan Mutation Detection Assays. Looking ahead, they are still on track to release their most innovative product yet, Ion Proton, on schedule in mid and late 2012. They expect next quarter’s revenue to be flat with a tax rate of 28.6%, similar to Q1’s tax rate. Life Technologies reiterated its outlook for 2012, still expecting organic revenue growth of 2-4%, resulting in adjusted EPS of $3.90-$4.05.

-Jorge Perez

Monday, May 21, 2012

Barclays (BCS) to Sell Entire Minority Holding in BlackRock (BLK)


When BlackRock acquired Barclays Global Investors in 2009 some of the payment was made in BlackRock common stock. Barclays remained a minority stakeholder in BlackRock as an investment over the past three years. With tightening capital requirements in accordance with new Basel laws coming into affect, Barclays needed to find extra capital.  Barclays holds a $6.1 Billion investment in BlackRock and plans to sell it entirely.
To counter the possible negative impact this might have on BlackRock’s share price, BlackRock’s management has arranged to purchase back $1 Billion of this stake.
Barclays stake in BlackRock was a known risk and one that should be monitored closely in the upcoming months. A growing trend in the financial sector is the different ways firms are dealing with Basel capital ratio requirements. We expect this trend to continue through the end of 2012.
Timing does not seem to be a factor. Barclays needed the capital, therefore needed to sell their BlackRock investment regardless of BlackRock’s current market price.
S&P reaffirmed BlackRock’s credit rating as A+ with a stable outlook. S&P noted BlackRock’s operations remain strong and cash flows constant, following the Barclays announcement. 

Saturday, May 19, 2012

DVA F1Q12 Earnings 05/02/12 - (Ryan Kennedy)

DaVita Inc. reported positive results for the first quarter of the fiscal year. DVA posted EPS of $1.46 compared to street estimates of $1.45 per share, representing a 48% increase year-over-year. DaVita had revenues of $1.9 billion compared to $1.6 billion, or an increase of 19%. The gains were predominantly driven by increases in the amount of treatments per day, with approximately 68,000 treatments per day, or a 14% increase over the same quarter a year ago. Treatments per day grew by 6% organically, as the firm acquired 28 new treatment centers and opened up an additional 13 centers in the United States. Going forward, management raised guidance for the rest of 2012, and guided operating income from $1.20-1.30 billion to $1.23-1.31 billion. Since the release, the stock has fallen 8% based on broader market movements and Medicare changes which may negatively affect the reimbursement the firm receives.

Record Book Earnings


During the second quarter, John Deere was able to hit quarterly highs for both income and sales, and was the tenth straight quarter where thy reporter higher earnings quarter over quarter. Quarterly income cracked $1 Billion for the first time in company history, with revenues growing to over $10 Billon, giving the global giant year over year growth of over 12%. The company reported EPS of $2.61, which beat the market expectations of $2.54, a positive surprise of 2.76%. A big reason for this growth has been the growth in global farming, which according to CEO Sam Allen has shown impressive “strength and endurance.” The company has also successfully launched their major new product line, the engine-emission technology.


-Matt Buechele